Murchinson Ltd. bought a new position in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,000,000 shares of the company's stock, valued at approximately $4,230,000. OmniAb accounts for 1.2% of Murchinson Ltd.'s investment portfolio, making the stock its 14th largest position. Murchinson Ltd. owned 0.85% of OmniAb as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of OABI. Vanguard Group Inc. boosted its holdings in shares of OmniAb by 1.1% during the first quarter. Vanguard Group Inc. now owns 5,713,539 shares of the company's stock worth $30,967,000 after purchasing an additional 62,131 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in OmniAb by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company's stock worth $146,000 after buying an additional 3,108 shares during the period. Simplicity Wealth LLC lifted its holdings in OmniAb by 23.3% in the second quarter. Simplicity Wealth LLC now owns 42,160 shares of the company's stock worth $158,000 after buying an additional 7,976 shares during the period. Towerview LLC lifted its holdings in OmniAb by 114.0% in the second quarter. Towerview LLC now owns 535,000 shares of the company's stock worth $2,006,000 after buying an additional 285,000 shares during the period. Finally, Isthmus Partners LLC lifted its holdings in OmniAb by 37.2% in the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company's stock worth $1,981,000 after buying an additional 143,387 shares during the period. 72.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have commented on OABI. HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th. Benchmark restated a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $7.00 target price on shares of OmniAb in a research note on Friday, August 16th.
View Our Latest Report on OABI
OmniAb Stock Performance
Shares of OABI traded down $0.08 on Wednesday, hitting $3.83. 356,873 shares of the stock traded hands, compared to its average volume of 504,487. The company has a market capitalization of $540.87 million, a PE ratio of -6.31 and a beta of -0.14. The business has a 50 day simple moving average of $4.06 and a 200 day simple moving average of $4.21. OmniAb, Inc. has a one year low of $3.56 and a one year high of $6.72.
About OmniAb
(
Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
See Also
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
